Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mecbotamab vedotin (Primary) ; Nivolumab (Primary)
  • Indications Adenocarcinoma; Bone cancer; Malignant fibrous histiocytoma; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Sarcoma; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions; First in man; Registrational; Therapeutic Use
  • Sponsors BioAtla

    • Most Recent Events

    • 14 May 2024 According to a Bioatla media release, company completed enrollment of initial 20 patients at 1.8 mg/kg 2Q3W regimen and Anticipate meeting with the FDA for guidance on the remaining portion of the potentially registrational trial in 2H 2024.
    • 17 Apr 2024 Planned number of patients changed from 120 to 300.
    • 26 Mar 2024 According to a Bioatla media release, Phase 2 potentially registrational study in undifferentiated pleomorphic sarcoma (UPS) on track to complete enrollment of approximately 20 patients in April, Anticipate FDA meeting for guidance on the remaining portion of the registration trial in 2H 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top